logo
Plus   Neg
Share
Email

Stock Alert: Astrotech Up 10%

Shares of Astrotech Corp. (ASTC) are gaining nearly 10% on Wednesday after the micro-cap company's subsidiary and Cleveland Clinic ink a deal for to develop a rapid COVID-19 breath test.

ASTC is currently trading at $2.3899, down $0.2099 or 9.6284%, on the Nasdaq.

Astrotech said its subsidiary BreathTech Corp. has inked a deal with the Cleveland Clinic Foundation. Under the deal, BreathTech's BreathTest-1000 will be used to compare exhaled breath from individuals who have tested positive on a COVID-19 polymerase chain reaction test with that from subjects who have had a negative COVID-19 PCR test.

The goal of the pilot study will be to analyze different volatile organic compounds from the breath to evaluate the correlation with different disease states.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT